Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
OBX-115
- Development stage
- Phase 2
- Lead developer
- Obsidian Therapeutics
- Modality
- Vaccines & Immunotherapeutics, Tumor-Infiltrating Lymphocytes (TILs) → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
OBX-115 is an engineered tumor-infiltrating lymphocyte (TIL) cell therapy developed by Obsidian Therapeutics. It is designed to treat checkpoint inhibitor-resistant metastatic melanoma and other solid tumors. OBX-115 utilizes a pharmacologically regulatable membrane-bound IL-15 (mbIL15) system, eliminating the need for co-administration of interleukin-2 (IL2), which is typically required in traditional TIL therapies. This approach aims to improve safety and efficacy by enhancing antitumor activity and persistence of the TIL cells.
- Brand names
- cytoTIL15cytoTIL-15cytoTIL 15
- Other names
- cytoTIL 15cytoTIL15cytoTIL-15IL15-CA2 DRD modified T cellsIL-15-CA2 DRD modified T cellsIL 15-CA2 DRD modified T cells
02
Targets
IL-15R (Interleukin 15 receptor alpha/interleukin 15 complex)
Beyond the preview
Go deeper on OBX-115.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on OBX-115.